Previous close | 1.4500 |
Open | 1.4500 |
Bid | 1.0000 |
Ask | 1.5000 |
Strike | 5.00 |
Expiry date | 2024-06-21 |
Day's range | 1.4500 - 1.4500 |
Contract range | N/A |
Volume | |
Open interest | 11 |
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.